

Breast Cancer HER-2 Negative Breast Cancer

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

Trial Status
Completed

Trial Runs In
42 Countries

Trial Identifier
NCT01358877
TOC4939G,2010-022902-41,BIG
4-11 BO25126

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This randomized, double-blind, placebo-controlled, two-arm study will assess the safety and efficacy of pertuzumab in addition to chemotherapy plus trastuzumab as adjuvant therapy in participants with operable HER2-positive primary breast cancer. This study will be carried out in collaboration with the Breast International Group (BIG).

Hoffmann-La Roche
Sponsor

Phase 3
Phase

NCT01358877 TOC4939G,2010-022902-41,BIG 4-11 BO25126
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No
